---
layout: default
title: Anastrozole
description: "Anastrozole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æœ€é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 23
evidence_level: L1
indication_count: 6
---

# Anastrozole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Anastrozoleï¼šå¾åœç¶“å¾Œä¹³ç™Œåˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Anastrozole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Anastrozole åŸæœ¬ç”¨æ–¼æ²»ç™‚åœç¶“å¾Œå©¦å¥³æ™šæœŸä¹³ç™ŒåŠè¼”åŠ©æ²»ç™‚æ—©æœŸä¹³ç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **50+ å€‹è‡¨åºŠè©¦é©—**å’Œ **20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åœç¶“å¾Œå©¦å¥³æ™šæœŸä¹³ç™Œã€è·çˆ¾è’™æ¥å—å™¨é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©æ²»ç™‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€ç¥ç¶“æ¯ç´°èƒç˜¤ã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€ganglioneuroblastoma (disease)ã€è…¹è†œå¾Œè…«ç˜¤ã€å–®æ ¸ç´°èƒç™½è¡€ç—… |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.68% |
| è­‰æ“šç­‰ç´š | L1 |
| å°ç£ä¸Šå¸‚ | æœ‰ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Already Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§) |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.68%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Anastrozole æ˜¯ç¬¬ä¸‰ä»£éé¡å›ºé†‡èŠ³é¦™ç’°é…¶æŠ‘åˆ¶åŠ‘ï¼Œå…¶ä½œç”¨æ©Ÿè½‰ï¼š

1. **æŠ‘åˆ¶èŠ³é¦™ç’°é…¶**ï¼šé¸æ“‡æ€§æŠ‘åˆ¶èŠ³é¦™ç’°é…¶ï¼ˆCYP19ï¼‰ï¼Œé˜»æ–·é›„æ¿€ç´ è½‰åŒ–ç‚ºé›Œæ¿€ç´ 
2. **é™ä½é›Œæ¿€ç´ æ¿ƒåº¦**ï¼šå¯å°‡åœç¶“å¾Œå©¦å¥³è¡€æ¸…é›Œæ¿€ç´ æ¿ƒåº¦é™ä½ç´„80-90%
3. **æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·**ï¼šå°é›Œæ¿€ç´ å—é«”é™½æ€§ä¹³ç™Œï¼Œæ¸›å°‘é›Œæ¿€ç´ åˆºæ¿€å¯æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·

é æ¸¬é©æ‡‰ç—‡ã€Œå¥³æ€§ä¹³è…ºç™Œã€èˆ‡åŸé©æ‡‰ç—‡é«˜åº¦é‡ç–Šï¼Œæ­¤é æ¸¬å°è­‰äº†æ¨¡å‹å° anastrozole åœ¨ä¹³ç™Œæ²»ç™‚ä¸­è§’è‰²çš„æ­£ç¢ºè­˜åˆ¥ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT03778931](https://clinicaltrials.gov/study/NCT03778931) | Phase 3 | COMPLETED | 478 | Elacestrant vs AI åœ¨ CDK4/6 æŠ‘åˆ¶åŠ‘å¤±æ•—å¾Œçš„ ER+/HER2- ä¹³ç™Œ |
| [NCT03822468](https://clinicaltrials.gov/study/NCT03822468) | Phase 2 | COMPLETED | 376 | Ribociclib 400mg + AI åœ¨æ™šæœŸä¹³ç™Œçš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ |
| [NCT02441946](https://clinicaltrials.gov/study/NCT02441946) | Phase 2 | COMPLETED | 224 | Abemaciclib + Anastrozole æ–°è¼”åŠ©æ²»ç™‚ï¼ŒKi67 é¡¯è‘—ä¸‹é™ |
| [NCT00287534](https://clinicaltrials.gov/study/NCT00287534) | Phase 2 | COMPLETED | 1059 | Tamoxifen 2å¹´å¾Œè½‰ Anastrozole 3å¹´ vs æŒçºŒ Tamoxifen 5å¹´ |
| [NCT02206984](https://clinicaltrials.gov/study/NCT02206984) | Phase 2 | COMPLETED | 201 | ä¾µçŠ¯æ€§ä¹³å°è‘‰ç™Œå°å…§åˆ†æ³Œæ²»ç™‚åæ‡‰è©•ä¼° |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [31839281](https://pubmed.ncbi.nlm.nih.gov/31839281/) | 2020 | RCT | Lancet | IBIS-II é•·æœŸè¿½è¹¤ï¼šAnastrozole é é˜²é«˜é¢¨éšªå©¦å¥³ä¹³ç™Œï¼Œæ•ˆæœæŒçºŒè‡³åœè—¥å¾Œ |
| [15639680](https://pubmed.ncbi.nlm.nih.gov/15639680/) | 2005 | RCT | Lancet | ATAC è©¦é©—5å¹´çµæœï¼šAnastrozole å„ªæ–¼ Tamoxifenï¼Œå»¶é•·ç„¡ç—…å­˜æ´»æœŸ |
| [26686313](https://pubmed.ncbi.nlm.nih.gov/26686313/) | 2016 | RCT | Lancet | IBIS-II DCISï¼šAnastrozole vs Tamoxifen é é˜² DCIS å¾©ç™¼ï¼Œç™‚æ•ˆç›¸ç•¶ |
| [28614542](https://pubmed.ncbi.nlm.nih.gov/28614542/) | 2017 | Review | Rev Assoc Med Bras | Anastrozole åœ¨ä¹³ç™ŒåŒ–å­¸é é˜²èˆ‡æ²»ç™‚çš„æ–‡ç»å›é¡§ |
| [16439860](https://pubmed.ncbi.nlm.nih.gov/16439860/) | 2006 | Review | Oncology | Anastrozole å¾æ™šæœŸåˆ°æ—©æœŸä¹³ç™ŒåŠé é˜²çš„å®Œæ•´æ‡‰ç”¨ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.53%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. vertebral anomalies and variable endocrine and T-cell dysfunction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.42%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. ganglioneuroblastoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.41%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.41%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. retroperitoneal neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.33%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.33%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. monocytic leukemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.16%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.16%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|---------|------|------|-------------|------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬022282è™Ÿ | å®‰ç¾é”éŒ 1æ¯«å…‹ | è†œè¡£éŒ  | è‡ºç£é˜¿æ–¯ç‰¹æ·åˆ©åº· | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬047539è™Ÿ | å®‰ç´æŸ”è†œè¡£éŒ  | è†œè¡£éŒ  | å°ç£æ±æ´‹è—¥å“ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬055555è™Ÿ | åŸ¹åŠ›å®‰è«¾å¦¥è†œè¡£éŒ  | è†œè¡£éŒ  | åŸ¹åŠ›è—¥å“ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬056730è™Ÿ | æè¼å®‰å¨œæ–¯æŸ”è†œè¡£éŒ  | è†œè¡£éŒ  | æè¼è—¥å“ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026515è™Ÿ | å®‰ç‘ç‰¹è†œè¡£éŒ  | è†œè¡£éŒ  | å‡±æ²›çˆ¾è—¥å“ | æœ‰æ•ˆ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | éç´°èƒæ¯’æ€§ï¼ˆè·çˆ¾è’™ç™‚æ³•ï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | æ¥µä½ |
| è‡´åæ€§åˆ†ç´š | æ¥µä½ |
| ç›£æ¸¬é …ç›® | éª¨å¯†åº¦ã€è¡€è„‚ã€è‚åŠŸèƒ½ |
| è™•ç½®é˜²è­· | ä¸€èˆ¬è—¥ç‰©è™•ç½®å³å¯ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - èˆ‡ Tamoxifen ä½µç”¨æœƒé™ä½ anastrozole è¡€ä¸­æ¿ƒåº¦ï¼Œä¸å»ºè­°åˆä½µä½¿ç”¨
  - èˆ‡å«é›Œæ¿€ç´ è£½åŠ‘ä½µç”¨æœƒé™ä½ç™‚æ•ˆ
- **ä¸»è¦å‰¯ä½œç”¨**ï¼š
  - éª¨è³ªç–é¬†ã€éª¨æŠ˜é¢¨éšªå¢åŠ 
  - é—œç¯€ç—›ã€è‚Œè‚‰ç—›ï¼ˆç´„50%æ‚£è€…ï¼‰
  - æ½®ç´…ã€ç›œæ±—
  - è¡€è„‚ç•°å¸¸
- **ç¦å¿Œç—‡**ï¼š
  - åœç¶“å‰å©¦å¥³
  - æ‡·å­•åŠå“ºä¹³æœŸ
  - åš´é‡è‚åŠŸèƒ½ä¸å…¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šè‘¡è„æŸšå° Anastrozole å½±éŸ¿è¼ƒå°
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**å¿ƒè¡€ç®¡ç–¾ç—… (Cardiovascular Diseases)** ğŸŸ¡ Moderate
- In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.

**Hypercholesterolemia** ğŸŸ¡ Moderate
- During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these pat...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate h...

**éª¨è³ªç–é¬†ç—‡ (Osteoporosis)** ğŸŸ¡ Moderate
- Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when p...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šAlready Approved (åŸé©æ‡‰ç—‡ç¯„åœå…§)**

**ç†ç”±ï¼š**
é æ¸¬é©æ‡‰ç—‡ã€Œå¥³æ€§ä¹³è…ºç™Œã€å¯¦éš›ä¸Šæ˜¯åŸæ ¸å‡†é©æ‡‰ç—‡çš„ä¸€èˆ¬æ€§æè¿°ã€‚Anastrozole å·²æ˜¯åœç¶“å¾Œè·çˆ¾è’™å—é«”é™½æ€§ä¹³ç™Œçš„æ¨™æº–æ²»ç™‚è—¥ç‰©ä¹‹ä¸€ã€‚å¤§é‡è‡¨åºŠè©¦é©—ï¼ˆå¦‚ ATACã€IBIS-IIï¼‰å·²è­‰å¯¦å…¶ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ã€‚

**è‡¨åºŠå»ºè­°ï¼š**
- é™ç”¨æ–¼åœç¶“å¾Œå©¦å¥³æˆ–åµå·¢åŠŸèƒ½æŠ‘åˆ¶å¾Œçš„å©¦å¥³
- å®šæœŸç›£æ¸¬éª¨å¯†åº¦ï¼Œå¿…è¦æ™‚çµ¦äºˆéª¨è³ªä¿è­·åŠ‘
- æ³¨æ„é—œç¯€ç—‡ç‹€çš„è™•ç†ï¼Œä»¥æå‡æ²»ç™‚é †å¾æ€§
- èˆ‡ CDK4/6 æŠ‘åˆ¶åŠ‘ä½µç”¨å¯é€²ä¸€æ­¥æå‡æ™šæœŸä¹³ç™Œç™‚æ•ˆ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Docetaxel]({{ "/drugs/docetaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - è­‰æ“šç­‰ç´š L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Anastrozoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/anastrozole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_anastrozole,
  title = {Anastrozoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/anastrozole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
